3'-O-(2-nitrobenzyl)-2'-dATP Incorporation and Removal Characterization with PAGE Assisted Precision Version 1

Written by Michael Uttmark

Not Peer Reviewed For the Stanford Student Space Initiative Biology Sub team

Written: November 8, 2017 Performed: November 8, 2017 Printed: 10:53, 26th November, 2017

1 Procedure Purpose

Determine if the modified nucleotide, 3'-O-(2-nitrobenzyl)-2'-dATP, can be noticeably incorporated and then removed by Terminal Deoxynucleotidyl Transferase in "standard conditions".

Figure 1: 3'-O-(2-nitrobenzyl)-2'-dATP

2 Overview

This lab will attempt to append 3'-O-(2-nitrobenzyl)-2'-dATP to a **short (25bp) primer**. The effectiveness of this attempt will be determined by attempting to form a homopolymer on the modified primer. If a homopolymer is formed, the blocking groups did not effectively prevent their formation. Moreover, another sample will have their blocking groups removed by ultraviolet light (365nm) and the will be treated with the same dNTP extension process as the "blocked" sample. This could be due to many reasons (the most likely of which being that the blocking groups either (1) were appended without the 2' nitrobenzyl due to sample degradation or (2) were not appended). If the homopolymer was not formed (but a homopolymer was formed on the controls) it follows that the blocking groups prevented the formation of the homopolymer, likely due to them preforming their intended function. Moreover, all samples will be run on a PAGE gel to achieve single nucleotide resolution. This will allow us to confirm that the 3'-O-(2-nitrobenzyl)-2'-dATP is the only base appended to the "blocked" sample. A ddATP control will help determine the effectiveness of the blocking group as a positive control for effective blocking.

3 Safety Information

- 1. **SYBR Gold** has no data available addressing the mutagenicity or toxicity of SYBR Gold nucleic acid gel stain. Because this reagent binds to nucleic acids, it should be treated as a potential mutagen and handled with appropriate care. The DMSO stock solution should be handled with particular caution as DMSO is known to facilitate the entry of organic molecules into tissues.[?]
- 2. **Terminal Deoxynucleotidyl Transferase** is toxic if inhaled. May cause cancer. Toxic to aquatic life with long lasting effects. Avoid breathing dust/fume/gas/mist/vapours/spray. Use personal protective equipment as required. If Inhaled: Remove victim to fresh air and keep at rest in a position comfortable for breathing. Dispose of contents/container in accordance with local/regional/national/international regulations.[?]
- 3. **Terminal Deoxynucleotidyl Transferase Buffer** may cause cancer. It is also a skin irritant. However, ingestion/inhalation is not expected to present a significant ingestion hazard under anticipated conditions of normal use. If you feel unwell, seek medical advice.
- 4. Working in a communal lab space is dangerous. Do not assume your fellow workers cleaned up sufficiently

4 Materials

- Primer (25bp)
- 100mM 3'-O-(2-nitrobenzyl)-2'-dATP Stock
- 10mM dNTP Stock
- 100mM dATP Stock
- 10mM ddATP Stock
- 5X Terminal Deoxynucleotidyl Transferase Buffer
- Terminal Deoxynucleotidyl Transferase Stock ($20U/\mu L$)
- Nuclease Free Water
- TBE Buffer
- 20% Urea Denaturing Gels
- SYBR Gold
- 365nm UV Radiation Source (We will be using our "UV Death Chamber")

5 Procedure

5.1 Sample Preparation

- 1. Remove 3'-O-(2-nitrobenzyl)-2'-dATP, Terminal Deoxynucleotidyl Transferase, primer, Terminal Deoxynucleotidyl Transferase buffer, ddATP stock and dATP stock from -20°C freezer
- 2. Let 3'-O-(2-nitrobenzyl)-2'-dATP thaw on ice in dark
- 3. Other reagents can thaw on ice in the light





A	The primer incubated with dATP and then commercial dNTPs
B1	The primer incubated with just NBdATP
B2	The primer incubated with NBdATP and then dNTPs
В3	The primer incubated with NBdATP, irradiated with 365nm ultraviolet light, and then dNTPs
B1*, B2* B3*	A repeat of B1, B2 and B3 prepared separately from B1, B2 and B3
\mathbf{C}	The primer incubated with just dNTPs in the second incubation
D	The primer incubated with ddATP nucleotides and then dNTPs
X	The primer incubated with $dNTPs$ but no $Terminal Deoxynucleotidyl Transferase$ in the second

Figure 2: Samples and their experimental conditions

5.2 Attempted blocking

- 4. Label four PCR Tubes A, B, B* and D, respectively
- 5. Pipette $10.6\mu L$ of nuclease free water into tube A
- 6. Pipette $19.8\mu L$ of nuclease free water into tube B and B*
- 7. Pipette $11\mu L$ of nuclease free water into tube D
- 8. Pipette 4.0μ L 5X Terminal Deoxynucleotidyl Transferase reaction buffer into PCR Tubes A and D
- 9. Pipette 6.0μ L 5X Terminal Deoxynucleotidyl Transferase reaction buffer into PCR Tube B and B*
- 10. Dilute Nucleotides:
 - (a) Label a PCR Tube "dATP Dilute"
 - (b) Pipette 9μ L of nuclease free water into PCR Tube
 - (c) Pipette 1μ L of dATP stock into PCR Tube
 - (d) Vortex directly before use
- 11. Pipette $0.5\mu L$ of primer into PCR Tubes A and D
- 12. Pipette $0.75\mu L$ of primer into B and B*
- 13. Pipette $3\mu L$ of dATP dilute into PCR Tube A
- 14. Pipette $0.45\mu L$ of 3'-O-(2-nitrobenzyl)-2'-dATP stock into PCR Tube B and B*
- 15. Pipette $3\mu L$ of ddATP **10mM stock** into PCR Tube D
- 16. Gently pipette 2μ L Terminal Deoxynucleotidyl Transferase($15/\mu$ L) into PCR tubes A and D.
- 17. Gently pipette 4µL Terminal Deoxynucleotidyl Transferase(15/µL) into PCR tube B and B*.
- 18. Incubate samples at 37°C for 30 minutes
- 19. Return dATP and ddATP to -20°C freezer.

OPTIONAL STOP POINT





5.3 Extending 5 PROCEDURE

5.3 Extending

Based off our standard Terminal Deoxynucleotidyl Transferase extending procedure [?].

- 20. Label two PCR Tubes C and X, respectively
- 21. Pipette 10.5μ L nuclease free water into PCR Tube C (see above, ATTEMPTED BLOCKING)
- 22. Pipette $12.5\mu L$ of nuclease free water into PCR Tube X (see above, **CONTROLS**)
- 23. Pipette $0.5\mu L$ of primer into both PCR Tubes
- 24. Pipette 4.0µL 5X Terminal Deoxynucleotidyl Transferase reaction buffer into PCR Tube C and X
- 25. Pipette $3\mu L$ of dNTP stock into PCR Tubes C and X
- 26. Set PCR Tube X aside.
- 27. Wait until the previous samples have finished incubating
- 28. Label two PCR Tubes "B1" and "B1*
- 29. Label two PCR Tubes "B3" and "B3*
- 30. Relabel PCR Tubes B and B* as B2 and B2* respectively
- 31. Pipette $10\mu L$ from B2 into B1
- 32. Pipette $10\mu L$ from B2* into B1*
- 33. Pipette $10\mu L$ from B2 into B3
- 34. Pipette 10μ L from B2* into B3*
- 35. Pipette 2μ L EDTA into **B1 and B1*** to stop the reaction [?]
- 36. Pipette 2μ L nuclease free water into B1 and B1*
- 37. Place B1 and B1* into -20°C freezer for later use
- 38. Expose B3 and B3* to 365nm of ultraviolet light for 15 minutes with UV deathchamber, or 30 minutes with flashlight if chamber is not available B3* was irradiated first at 80mA for 15 minutes and B3 was irradiated at 200mA for 15 minutes.
- 39. Pipette $.4\mu$ L of dNTP stock into PCR Tubes **A**
- 40. Pipette $.4\mu$ L of dNTP stock into PCR Tubes **B2**
- 41. Pipette $.4\mu$ L of dNTP stock into PCR Tubes **B3**
- 42. Pipette .4μL of dNTP stock into PCR Tubes **B2***
- 43. Pipette $.4\mu$ L of dNTP stock into PCR Tubes **B3*** Please check these off as you go it's easy to miss one.
- 44. Gently pipette 2μ L Terminal Deoxynucleotidyl Transferase (20 U/ μ L) into **PCR Tube C** and **B3** along with **B3***
- 45. Incubate all samples except B1 and B1* at 37°C for 30 minutes
- 46. Wait until the samples have finished incubating.
- 47. Stop any Terminal Deoxynucleotidyl Transferaseaction by adding 2μ L 0.5M EDTA to the all PCR tubes **except all B and B*** after incubation.[?]
- 48. Pipette 1μ L 0.5M EDTA into B2 and B2*





5.4 Analysis 5 PROCEDURE

49. Pipette 1μ L 0.5M EDTA into B3 and B3*

RECOMMENDED STOP POINT

5.4 Analysis

5.4.1 XCell Surelock Setup and Pre-Run

- 50. Remove 20% polyacrylamide gel from pouch and rinse with deionized water.
- 51. Peel off tape on bottom of 20% polyacrylamide gel and remove the comb.
- 52. Lower the Buffer Core (the piece that holds the gels) into the Lower Buffer Chamber so that the negative electrode fits into the opening in the gold plate.
- 53. Insert the Gel Tension Wedge into the XCell Surelock behind the buffer core. Make sure it is in its 'unlocked' position, which allows the wedge to slip into the unit.
- 54. Insert gel cassettes into the lower buffer chamber. The shorter "well" side of the cassette faces into the buffer core. The slot on the back must face outward. If only one gel is being run, insert a buffer dam in the place of a gel cassette.
- 55. Pull forward on the Gel Tension Lever toward the buffer core until the gel cassettes are snug against the buffer core. This puts it in the 'locked' position.
- 56. Fill the Upper Buffer Chamber (between the gels) with running buffer. Ensure it is not leaking.
- 57. Fill the Lower Buffer Chamber completely with running buffer by pouring TBE next to the Gel Tension Wedge.
- 58. Pipette 12μ L of running buffer into each gel well.
- 59. Place the gel cover on the apparatus in the correct orientation. Connect the electrodes to the power source, and pre-run the gel for 30 minutes at 150V.
- 60. When there is only 5 minutes left on the incubation, retrieve sample B1 and B1* from the freezer and let thaw on ice

5.4.2 Run Gel

Note: Be relatively swift about mixing and loading, as the samples will gradually begin to evaporate if left on the parafilm for too long.

- 61. Obtain a sizable piece of parafilm. Pipette 3 μ L of 2X Gel Loading Dye in a row of 15 droplets.
- 62. For the 10/60 Ladder samples, pipette 1uL of 10/60 Ladder and 4 uL of running buffer and mix.
- 63. For the remaining droplets, add 3 μ L of the appropriate sample. See the corresponding table (Figure ??) above for sample location and order.
- 64. As you go, pipette up and down to mix thoroughly.
- 65. Load the gels (with 5 μ L sample in each well) when they are finished pre-running. Ensure pipette tip is fully in the well, and depress slowly and carefully. Work quickly to minimize diffusion.
- 66. Run the gel(s) at 150V until the dark blue dye is at the bottom.





5.4 Analysis 5 PROCEDURE

Well number	Sample
1	10/60 DNA Ladder
2	Custom Ladder (40ng)
3	B1 (40ng)
4	B2 (40ng)
5	B3 (40ng)
6	B1* (40ng)
7	B2* (40ng)
8	B3* (40ng)
9	X (40ng)
10	D (40ng)
11	C From last procedure (40ng)
12	A (40ng)
13	C (40ng)
14	Custom Ladder (40ng)
15	10/60 DNA Ladder

Figure 3: Wells and their assorted reagents

5.4.3 Stain & View Gel

- 67. While the gel runs, prepare 1X SYBR Gold Staining Solution with TBE as dilute
 - (a) Add 6μ L SYBR Gold to 60μ L of TBE running buffer
- 68. Once gel has finished running, *lightly* agitate gel while submerged in solution for 60 minutes.
- 69. Review gel with gel viewer. Until unnecessary, place gel back in stain for 20-minute increments and re-image.
- 70. Post pictures to Slack.

Stop Procedure

- 1. Pipette samples into PCR tubes if not already contained in an appropriate manner
- 2. Label containers if not already labeled
- 3. Freeze samples at -20°C





6 Analysis




Figure 4: PAGE Gel used to determine length of samples

In this gel we have the samples enumerated in Figure 4 above. L is used as an abbreviation for the 10/60 DNA Ladder and CL is used as an abbreviation for the Custom Ladder prepared previously. Below, we have a comparison of the samples with our predicted results:

All samples from this experiment support the

Sample	Predicted if Blocking Occurred	Predicted if No Blocking Occurred	Observed $\frac{B}{B^*}$
B1	В	×	×
	n.	,	×
B2	В	✓	√
В3	\checkmark	\checkmark	√
X	X	×	×
D	В	В	В
A	✓	✓	√
С	✓	✓	√

Figure 5: Samples and Extension

conclusion that **blocking did not occur**. However, the past procedures both contradict and support this conclusion. Below, we have a similar table that includes the past procedures with relevant data:

As one can see from the results in the table above in Figure 6, our results have not been entirely consistent. The results seem to currently favour the conclusion that we are not blocking successfully. This is concerning, not simply because blocking is our goal, but because this experiment has already been preformed by another group with great success. Moreover, the only consistent results come from B1, who (with the exception of B3) has the least repetitions.

Our solution to this issue of repeatability is the (1) review our past experiments and look for changes and (2) run a "mega-replicate" experiment that puts our focus on solely B1 and B2, allowing us to do many replicates and nail down what is really happening.





Sample	Predicted if Blocking Occurred	Predicted if No Blocking Occurred	Observed $\frac{B}{B^*}$			
Sample			Agarose	4	5	Current
B1	В	X			×	×
					×	×
B2	В	/	$\mathbf{B}/$ $ imes$	√	√	$\overline{\hspace{1cm}}$
D2	В	V			×	\checkmark
B3	/	($\overline{\hspace{1cm}}$
БЭ	V	V				\checkmark
X	×	×	X	×	×	×
D	В	В		В	В	В
A	✓	✓	√	√	√	\checkmark
\overline{C}	✓	\checkmark	√	√	√	\checkmark

Figure 6: Samples and Extension Across Multiple Experiment




Figure 7: PAGE Gel used to determine length of samples (Large) $\,$



